Plasma β2-microglobulin and cerebrospinal fluid biomarkers of Alzheimer’s disease pathology in cognitively intact older adults: the CABLE study

[1]  F. Chiti,et al.  Amyloid fibrils act as a reservoir of soluble oligomers, the main culprits in protein deposition diseases , 2022, Bioessays.

[2]  Jianfeng Luo,et al.  Kidney function and dementia risk in community-dwelling older adults: the Shanghai Aging Study , 2021, Alzheimer's Research & Therapy.

[3]  L. Tan,et al.  Association of serum Apolipoprotein B with cerebrospinal fluid biomarkers of Alzheimer’s pathology , 2020, Annals of clinical and translational neurology.

[4]  L. Tan,et al.  Dynamic changes of CSF sTREM2 in preclinical Alzheimer’s disease: the CABLE study , 2020, Molecular Neurodegeneration.

[5]  M. Hotopf,et al.  Associations Between Depression, Arterial Stiffness, and Metabolic Syndrome Among Adults in the UK Biobank Population Study: A Mediation Analysis. , 2020, JAMA psychiatry.

[6]  D. Holtzman,et al.  Alzheimer Disease: An Update on Pathobiology and Treatment Strategies , 2019, Cell.

[7]  Young Hee Jung,et al.  Application of an amyloid and tau classification system in subcortical vascular cognitive impairment patients , 2019, European Journal of Nuclear Medicine and Molecular Imaging.

[8]  D. Y. Lee,et al.  Clinical and Biomarker Characteristics According to Clinical Spectrum of Alzheimer’s Disease (AD) in the Validation Cohort of Korean Brain Aging Study for the Early Diagnosis and Prediction of AD , 2019, Journal of clinical medicine.

[9]  Y. Hong,et al.  Prediction of Alzheimer's Pathological Changes in Subjective Cognitive Decline Using the Self-report Questionnaire and Neuroimaging Biomarkers , 2019, Dementia and neurocognitive disorders.

[10]  Charlotte E. Ridler.  Alzheimer disease: Blood amyloid-β successfully signals AD , 2018, Nature Reviews Neurology.

[11]  C. Rowe,et al.  High performance plasma amyloid-β biomarkers for Alzheimer’s disease , 2018, Nature.

[12]  V. Savalei,et al.  Type I Error Rates and Power of Several Versions of Scaled Chi-Square Difference Tests in Investigations of Measurement Invariance , 2017, Psychological methods.

[13]  R. Thome,et al.  MHC-I and PirB Upregulation in the Central and Peripheral Nervous System following Sciatic Nerve Injury , 2016, PloS one.

[14]  Gregor Bieri,et al.  β2-microglobulin is a systemic pro-aging factor that impairs cognitive function and neurogenesis , 2015, Nature Medicine.

[15]  Carla J. Shatz,et al.  Synapse elimination and learning rules coregulated by MHC Class I H2-Db , 2014, Nature.

[16]  C. Jack,et al.  An operational approach to National Institute on Aging–Alzheimer's Association criteria for preclinical Alzheimer disease , 2012, Annals of neurology.

[17]  W. Freeman,et al.  Neuroglial Expression of the MHCI Pathway and PirB Receptor Is Upregulated in the Hippocampus with Advanced Aging , 2012, Journal of Molecular Neuroscience.

[18]  C. Shatz,et al.  Neuroprotection from Stroke in the Absence of MHCI or PirB , 2012, Neuron.

[19]  J. Kaye,et al.  The aging systemic milieu negatively regulates neurogenesis and cognitive function , 2011, Nature.

[20]  Denise C. Park,et al.  Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[21]  A. McAllister,et al.  MHCI negatively regulates synapse density during the establishment of cortical connections , 2011, Nature Neuroscience.

[22]  C. Rowe,et al.  Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging , 2010, Neurobiology of Aging.

[23]  A. Fagan,et al.  APOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal aging , 2010, Annals of neurology.

[24]  Kristina D. Micheva,et al.  Classical MHCI Molecules Regulate Retinogeniculate Refinement and Limit Ocular Dominance Plasticity , 2009, Neuron.

[25]  C. Shatz,et al.  MHC Class I: An Unexpected Role in Neuronal Plasticity , 2009, Neuron.

[26]  G. Alexander,et al.  Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease , 2009, Proceedings of the National Academy of Sciences.

[27]  Carla J. Shatz,et al.  Regulation of CNS synapses by neuronal MHC class I , 2007, Proceedings of the National Academy of Sciences.

[28]  J. Schneider,et al.  Neuropathology of older persons without cognitive impairment from two community-based studies , 2006, Neurology.

[29]  Carla J. Shatz,et al.  Immune signalling in neural development, synaptic plasticity and disease , 2004, Nature Reviews Neuroscience.

[30]  J. Streffer,et al.  Transgenic animal models of Alzheimer's disease and related disorders: histopathology, behavior and therapy , 2004, Molecular Psychiatry.

[31]  D. Hochstrasser,et al.  A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease , 2003, Proteomics.

[32]  C. Shatz,et al.  Functional requirement for class I MHC in CNS development and plasticity. , 2000, Science.

[33]  M. Chopp,et al.  Intrastriatal Transplantation of Bone Marrow Nonhematopoietic Cells Improves Functional Recovery After Stroke in Adult Mice , 2000, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[34]  D. Mash,et al.  Neuropathological and neuropsychological changes in "normal" aging: evidence for preclinical Alzheimer disease in cognitively normal individuals. , 1998, Journal of neuropathology and experimental neurology.

[35]  J. Pounds,et al.  A nonlinear isobologram model with Box-Cox transformation to both sides for chemical mixtures. , 1998, Environmental health perspectives.

[36]  J. Kaldor,et al.  Predictive markers of AIDS dementia complex: CD4 cell count and cerebrospinal fluid concentrations of beta 2-microglobulin and neopterin. , 1996, The Journal of infectious diseases.

[37]  Cory B. Giles,et al.  CNS-wide Sexually Dimorphic Induction of the Major Histocompatibility Complex 1 Pathway With Aging , 2017, The journals of gerontology. Series A, Biological sciences and medical sciences.

[38]  Reisa A. Sperling,et al.  CAP—advancing the evaluation of preclinical Alzheimer disease treatments , 2016, Nature Reviews Neurology.

[39]  D. A. Kenny,et al.  The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. , 1986, Journal of personality and social psychology.